A recent study also reported that RORγ agonists increased the expression of CCR6 and CCL20 in Tc17 cells, and this might contribute to the better migration of Tc17 cells into the tumor and recruitment of Tc1 cells [9]. The gene discussed is CCL20; the disease is neoplasm.